Targeting menin: A paradigm shift in acute myeloid leukemia therapy

During the AML Hub Steering Committee Meeting on August 11, 2026, key opinion leaders met to discuss the role of menin inhibitors in the evolving treatment paradigm for patients with acute myeloid leukemia (AML). The meeting opened with a presentation by Joshua Zeidner, followed by a panel discussion featuring Gail Roboz, Charles Craddock, Selina Luger, and Lars Bullinger. During his presentation, Zeidner provides an overview of the mechanism of action of menin inhibitors and discusses the rationale for their use in patients with AML. He explores the clinical evidence for the use of menin inhibitors in patients with relapsed/refractory and newly diagnosed AML, both as a monotherapy and in combination with other agents, and across different patient populations. He concludes by highlighting the evolving role of menin inhibitors across treatment settings for patients with AML. The subsequent discussion focuses on patient eligibility for menin inhibitor combinations and regional differences in treatment strategies. Intended for healthcare professionals. This educational resource is independently supported by Kura Oncology. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.